Atezolizumab (Tecentriq)

Atezolizumab at a glance

Names: Atezolizumab is the generic name; Tecentriq® is a brand. Tecentriq Hybreza® contains atezolizumab with hyaluronidase-tqjs for injection under the skin. Hyaluronidase helps the medicine spread through the tissue beneath the skin.

Treatment category: Immunotherapy, specifically a PD-L1 immune checkpoint inhibitor. It may be prescribed alone or with other cancer medicines.

How it is given: A healthcare professional gives it through a drip into a vein or as a specially formulated injection into the thigh. There is no atezolizumab tablet. Intravenous schedules commonly use intervals of two, three or four weeks; the under-the-skin formulation is usually given every three weeks.

Remember: Attend monitoring appointments, report changes early, and carry your immunotherapy alert card. The benefits, risks and treatment duration depend on your individual plan. This guide principally addresses adult care; children's doses and formulation eligibility require specialist instructions.

What is atezolizumab, and how does it work?

Your immune system uses proteins called checkpoints to control its activity and protect healthy tissues. PD-L1 is one of these proteins. Some cancers use the PD-L1 pathway to reduce an immune attack.

Atezolizumab is a laboratory-made antibody that binds to PD-L1 and blocks this signal. This can allow immune cells called T cells to act against cancer. It does not work in everyone, and a response is not necessarily immediate.

Because the immune response becomes more active, it can also affect healthy organs. These reactions are called immune-related side effects. They differ from many chemotherapy effects and may require steroids, hormone replacement or other specialist treatment. Recognising symptoms early helps the team act before an inflammation becomes severe.

How your team decides whether it is suitable

Atezolizumab is used to treat certain cancers. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

When considering checkpoint immunotherapy, your doctor may check markers such as PD-L1 (programmed death-ligand 1), MMR (DNA mismatch repair), MSI (microsatellite instability) or TMB (tumour mutational burden). These tests look at different features of the cancer: an immune-related protein, how well DNA errors are repaired, changes in short repeated DNA sequences, or the number of genetic changes in the tumour.

Not everyone needs all these tests, and they are not interchangeable. Their relevance depends on the cancer type, stage and exact medicine or combination being considered. Some treatment plans require a particular test result; others do not. Discuss with your doctor which tests are relevant to you and how the results affect your options. A result alone does not guarantee that treatment will work.

Genetic or molecular tests may help determine whether another treatment is more appropriate. In selected settings, a blood test for tiny amounts of tumour DNA may influence treatment selection.

Discuss the aim of treatment, expected benefits, possible alternatives and what would lead to a change of plan. Having an autoimmune condition or a transplant requires particularly careful assessment. Suitability for one formulation does not automatically establish suitability for another. The under-the-skin product Tecentriq Hybreza must not be given to someone with a known allergy to its hyaluronidase component or other ingredients.

Before treatment starts

Share your medical history and medicines

Tell the team about previous immunotherapy and any reaction to it; autoimmune conditions such as inflammatory bowel disease, rheumatoid arthritis or lupus; lung inflammation or chest radiotherapy; and liver, kidney, heart, thyroid or other hormone problems. Mention diabetes, recent infections and any history of hepatitis or HIV.

Report an organ or tissue transplant, including a corneal graft, and any previous or planned donor stem-cell transplant. Immune checkpoint treatment can cause transplant rejection or serious transplant-related complications. This needs specialist discussion before treatment.

Bring a list of prescribed medicines, inhalers, creams, over-the-counter products, vitamins, herbal and Ayurvedic preparations. Include steroids and medicines that suppress immunity. Do not stop a prescribed medicine yourself. Tell staff about allergies, pregnancy, breastfeeding or plans for future children.

Tests and practical preparation

Initial checks usually include blood counts and tests of liver, kidney and thyroid function. Your team may also check glucose, electrolytes, pregnancy status and other hormones. Infection screening, including hepatitis testing, depends on your history, the treatment combination and local practice. Heart or lung investigations may be needed when symptoms or risk factors warrant them.

Record your usual bowel pattern, breathing, energy and any existing rash. This makes changes easier to recognise. Before going home, know how to reach your own oncology team's urgent advice service, including outside clinic hours. Save its details on your phone and share the plan with someone who helps you.

How treatment is given

Intravenous infusion

An infusion goes through a small cannula in the hand or arm, or an existing central line or port. A permanent line is not always necessary. If you have a line between visits, follow its cleaning and dressing instructions. Report redness, discharge, pain or swelling around it, or fever, promptly. The first infusion usually takes 60 minutes. If it is tolerated, later infusions may take 30 minutes. Allow extra time for assessment, blood results, preparation and any accompanying medicines.

Common adult schedules are 840 mg every two weeks, 1,200 mg every three weeks or 1,680 mg every four weeks. These are alternatives selected by the prescriber, not doses to choose yourself. The overall regimen determines the appropriate schedule.

Tell the nurse immediately about pain, swelling or leakage around a cannula, or chills, flushing, itching, wheezing, dizziness or chest or back discomfort during administration. The team can pause treatment and assess the cause.

Injection under the skin

The subcutaneous formulation is usually given over about seven minutes into the thigh every three weeks. It contains 1,875 mg of atezolizumab with an enzyme that assists injection. In the US this product is named Tecentriq Hybreza®; EU product information describes a subcutaneous Tecentriq presentation. These names describe formulation differences, not a claim about local availability.

Staff alternate suitable injection areas and avoid tender, bruised, hard or inflamed skin. Temporary soreness or a local skin reaction can occur. Report worsening redness, swelling, heat or pain, especially with fever. This is a healthcare-administered treatment, not an injection to prepare or give yourself. The hospital pharmacy normally manages storage, preparation and disposal. If you are asked to transport a supplied medicine, obtain product-specific instructions from the pharmacist first.

The infusion and injection products have different doses and preparation requirements. Your oncology team may arrange a switch using the appropriate product instructions; they are not interchangeable milligram-for-milligram.

Other medicines, observation and treatment duration

Premedication is not automatically required for everyone receiving atezolizumab alone. It may be used after a previous reaction or because another drug in your regimen requires it. Staff monitor you during administration and decide whether further observation is needed. Do not assume the seven-minute injection equals a seven-minute appointment.

Some plans have a defined end date; others continue while there is benefit and side effects remain manageable. Chemotherapy or a targeted medicine may have its own schedule and stopping point. Obtain information for every medicine you receive.

If an appointment is missed, contact the unit promptly to rearrange it. The team will reset the interval safely. A safety-related delay is different from simply missing a visit: do not resume treatment until the team has assessed the problem.

Monitoring and checking whether treatment is working

At appointments, report new symptoms even if they seem minor or unrelated. Blood tests can detect liver, kidney or thyroid changes before you feel unwell. Other checks depend on the accompanying medicines and your health.

Scans, examination and relevant disease-specific tests help assess response. The timing varies. Symptoms alone cannot reliably show whether treatment is working, and having few side effects does not mean it is ineffective.

Occasionally, immune activity complicates scan interpretation. Your oncologist may arrange further assessment before deciding what a change means. Do not assume worsening symptoms or a growing abnormality are a harmless immune response.

Treatment may be held while an infection, abnormal blood result or possible immune reaction is investigated. For atezolizumab, side effects are generally managed by withholding or stopping it rather than reducing its dose. Other medicines in the regimen may be adjusted differently.

Common side effects and how to manage them

People experience different combinations of effects. Frequency also changes when other medicines are added. The following are useful problems to recognise; they are not a prediction of what will happen to you.

Tiredness and reduced energy

Balance rest with gentle movement, and spread demanding activities across the week. Accept help with shopping or travel when needed. Report fatigue that is new, worsening or interfering with basic activities. Marked weakness, dizziness or faintness needs urgent assessment because hormone changes, anaemia or inflammation may be responsible.

Reduced appetite, nausea or vomiting

Try smaller, more frequent meals and regular drinks. Take prescribed anti-sickness medicine as directed. Report ongoing nausea, weight loss or difficulty eating so the team can offer treatment or dietetic advice. Repeated vomiting, inability to keep fluids down, dizziness or reduced urination needs urgent advice. Vomiting does not remove an infused or injected dose, so no replacement dose is needed.

Diarrhoea or a change in bowel pattern

Contact your oncology team's urgent advice service promptly for new diarrhoea or bowel movements more frequent than usual, even if you otherwise feel well. Bowel inflammation can worsen quickly. Record the number and appearance of stools; mention any increase in stoma output.

Drink small amounts frequently unless you have been told to restrict fluids. Do not simply take an over-the-counter anti-diarrhoeal and wait several days. Your team may need stool tests and may prescribe treatment. Blood or black stools, significant abdominal pain, fever or dehydration require urgent assessment.

Rash, itching or dry skin

Use gentle washing products, lukewarm water and a plain moisturiser. Protect exposed skin from strong sunlight. Report new rash or itching so staff can decide whether a treatment cream or further assessment is needed. Rapidly spreading rash, painful skin, blisters, peeling or sores involving the mouth, eyes or genitals require immediate medical attention.

Joint or muscle discomfort

Gentle movement and pacing may help mild aches. Check which pain medicine is appropriate, particularly if you have kidney problems or take blood thinners. Report persistent pain, swollen joints or difficulty with daily tasks. New true muscle weakness, drooping eyelids, swallowing difficulty or breathlessness needs urgent assessment rather than routine pain relief.

Cough, breathlessness or fever

These symptoms are reported during treatment but should not be treated as harmless expected effects. A new or worsening cough, breathing change or fever may reflect infection or inflammation. Contact the team promptly; severe breathlessness is an emergency. Avoid using a fever medicine to postpone assessment.

Effects of accompanying treatment

Chemotherapy can add hair loss, low blood counts, mouth soreness or nerve symptoms. Other partner drugs may add high blood pressure, bleeding risk or different organ effects. Follow the advice for the complete regimen. A new symptom should be reported without trying to decide which medicine caused it.

Less common but important side effects

Inflammation of the lungs, bowel, liver or kidneys

Lung inflammation, called pneumonitis, may cause cough, breathlessness or chest pain. Bowel inflammation, called colitis, can cause diarrhoea, bleeding and abdominal pain. Liver inflammation, called hepatitis, may first appear on blood tests; warning symptoms include yellow eyes or skin, dark urine, unusual bruising and pain under the right ribs.

Kidney inflammation, called nephritis, can cause reduced urine, blood in the urine or swelling, but may also be detected only by blood tests. Report these changes promptly. Several organs can be affected at the same time, and immune effects may begin after the last dose.

Thyroid, pituitary and adrenal problems

These glands make hormones that regulate energy, blood pressure and many other body functions. Inflammation may cause unusual tiredness, headache, changes in weight, feeling unusually cold or hot, palpitations, dizziness or altered mood. Tell the team promptly, particularly when symptoms occur together.

A severe headache with visual changes, collapse, confusion or profound weakness needs emergency assessment. Some hormone problems require long-term replacement treatment even after immunotherapy stops. If steroid replacement is prescribed for adrenal failure, follow the emergency and sick-day instructions and do not stop it abruptly.

Diabetes and pancreatic inflammation

Atezolizumab can occasionally trigger insulin-dependent diabetes. New intense thirst and frequent urination need urgent assessment. If these occur with vomiting, abdominal pain, deep or rapid breathing, drowsiness or confusion, seek emergency help immediately: these can signal a dangerous build-up of acids in the blood.

Persistent severe upper abdominal pain, sometimes spreading to the back, may indicate pancreatic inflammation and also needs urgent assessment.

Heart, muscle, nerve and eye problems

Rare inflammatory reactions can affect the heart or its surrounding lining, muscles, nerves, brain or eyes. Warning symptoms include chest pain, a racing or irregular heartbeat, new weakness, balance problems, confusion, double vision or eye pain. Some heart, muscle and nerve problems occur together. Seek emergency care for severe symptoms, new major weakness, difficulty swallowing or breathing, or sudden neurological changes. New eye pain or visual changes require urgent assessment even without other symptoms.

Severe skin, blood or widespread immune reactions

Blistering or peeling skin and painful mouth or genital sores can signal a serious skin reaction. Rare blood-cell disorders or widespread immune activation may cause persistent fever, unusual bruising, bleeding, marked pallor or rapid deterioration. Seek urgent help rather than waiting for your next blood test. The team will investigate other possible causes, including infection.

Infusion reactions and transplant complications

Allergic or infusion-related reactions can happen during treatment or afterwards. Sudden facial or throat swelling, wheezing, severe dizziness or collapse is an emergency. Notify the nurse immediately if you are still in the unit.

People with a transplant have additional risks of rejection or donor cells attacking healthy tissues. Their transplant and oncology teams must coordinate care before, during and after atezolizumab.

Other medicines, supplements and vaccinations

Have your oncology pharmacist check new medicines, including supplements and traditional remedies. Atezolizumab is broken down differently from many tablets, but that does not make every combination safe. Partner drugs may have important food or medicine interactions.

Steroids and other immune-suppressing medicines require coordination with the oncologist. They can affect immune activity, yet steroids are also essential treatment for some immune side effects. Take them exactly as prescribed and follow the tapering plan; do not avoid necessary treatment or stop abruptly because you are concerned about immunotherapy effectiveness.

Arrange vaccination advice before treatment or travel. Non-live vaccines, such as injected influenza and available non-live COVID-19 vaccines, can often be given, with timing agreed by the team. Do not receive a live vaccine without specialist clearance. The period of restriction depends on the whole regimen, steroid exposure and recovery; there is no single after-treatment interval suitable for everyone.

Everyday life during treatment

Eat a varied diet as tolerated and drink regularly, unless a medical condition requires fluid restriction. There is no special diet proven to make atezolizumab work better. Discuss alcohol if you have abnormal liver tests, nausea or other medicines that make it unsuitable.

Gentle walking and activity can support wellbeing. Adjust exercise if you are breathless, dizzy or unusually weak, and have those symptoms assessed. Work may be possible, but flexible hours and time for appointments can help. Do not drive or operate machinery when tired, dizzy, visually impaired or affected by sedating medicines.

Before travel, check appointment timing, access to urgent care and insurance requirements. Carry a treatment summary and alert card. Do not travel far from care with unexplained new symptoms. Let your dentist and other clinicians know about all your cancer medicines before procedures; chemotherapy, blood counts and partner drugs may change their plans.

Use routine hand hygiene and avoid close contact with people who are clearly infectious. Household contact, conversation and affection do not transmit atezolizumab. Sexual activity is usually a matter of comfort and health, but contraception and any regimen-specific advice about barrier protection still apply.

Fertility, contraception, pregnancy and breastfeeding

The effect of atezolizumab on human fertility is uncertain. Hormone problems and accompanying chemotherapy may affect reproductive health. Discuss sperm, egg or embryo preservation before treatment if future parenthood matters to you. Do not assume that absent periods or reduced fertility means pregnancy is impossible.

Atezolizumab may harm a developing baby. If you can become pregnant, use effective contraception during treatment and for at least five months after the last dose. If you can become pregnant, the team should check your pregnancy status before treatment starts. Contact the team promptly if pregnancy is suspected.

The reviewed atezolizumab labels do not specify a separate fixed contraception period for male patients. This does not establish that every combination is risk-free: obtain advice for all partner medicines, which may require additional precautions or longer periods.

Do not breastfeed during treatment. US prescribing information advises avoiding breastfeeding for at least five months after the last dose. EU information calls for an individual decision about stopping breastfeeding or treatment and does not specify the same fixed interval. Discuss a safe feeding plan and the timing of any restart with your oncology and maternity teams, considering every medicine received.

After treatment finishes

Continue follow-up and any recommended blood tests. Fatigue may improve gradually, while some hormone problems need ongoing treatment. Immune effects can develop months after treatment and occasionally later. Do not dismiss a new symptom because treatment has ended.

Keep the alert card and a record of medicines and treatment dates. Tell future clinicians about atezolizumab, including before surgery or a transplant. Continue contraception and breastfeeding precautions for the agreed period. If you are tapering steroids, confirm the plan and what to do if you become ill or symptoms return.

Frequently asked questions